Telmisartan improved cerebral blood flow in humans [35], reduced neurologic deficits and improved locomotor function after cerebral ischemia [22, 35], reduced inflammatory and oxidative stress markers [22], reduced low-density receptors and apolipoprotein E expression in the brain [28], and increased BDNF levels in the hippocampus [15]. The gene discussed is APOE; the disease is brain ischemia.